New drug used to treat breast cancer heralded as 'quite groundbreaking'
By Catholic Online (NEWS CONSORTIUM)
4/6/2014 (3 years ago)
Catholic Online (www.catholic.org)
An important treatment option in the fight against breast cancer may be waiting in the wings. Researchers say a new type of drug could help prevent advanced breast cancer from worsening. The potential is great for breast cancer patients, and makes for a potential blockbuster product for Pfizer.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.
LOS ANGELES, CA (Catholic Online) - Said drug cut in half the risk that cancer would worsen, or progress, researchers said. The median time before the disease progressed or the women died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.
"The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies," Dr. Richard S. Finn, a principal investigator in the study, says. Finn, an oncologist at the University of California, Los Angeles, called the results "quite groundbreaking."
No child need ever go to bed hungry -- Learn how you can help!
Known as palbociclib, the drug also appeared to prolong survival but not by a statistically significant amount. Those who received the drug lived a median of 37.5 months in contrast with 33.3 months for those in the control group.
The results from the Phase 2, or mid-stage, study were presented here at the annual meeting of the American Association for Cancer Research. Palbociclib is considered a jewel in Pfizer's product pipeline, with analysts predicting annual sales of billions of dollars. Amgen is entitled to an eight percent royalty on sales of the drug.
Some investors may have been letdown due to the drug, partly because they were not quite as good as interim results presented about halfway through the trial. At that point, the difference in median progression-free survival was 26.1 months for palbociclib versus 7.5 months for the control group.
Finn stresses that a statistically significant survival benefit should not have been expected at this point because only 61 of the 165 patients in the trial had died. Patients can use other drugs after leaving the trial, which can dilute any effect of palbociclib.
Palbociclib slows the proliferation of cancer cells by inhibiting the activity of two related enzymes involved in cell division; cyclin-dependent kinases 4 and 6.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor. While breast cancer is the initial focus, the drugs are being tested for other cancers.
Breast cancer specialists not involved in the study were encouraged -- but expressed caution. "These results are strikingly positive and with a large potential impact to patients," Dr. José Baselga said in a speech at the conference discussing the results.
Baselga, the physician in chief at the Memorial Sloan-Kettering Cancer Center, also said the results might have been biased because the study investigators, who determined whether tumors had progressed, knew which patients were getting palbociclib.
Dr. Eric P. Winer, chief of women's cancers at the Dana-Farber Cancer Institute in Boston, says larger studies were still needed.
"This is a small Phase 2 trial - not tiny, but not the kind of study that would typically lead to a change in practice," he said.
Copyright 2017 - Distributed by THE CALIFORNIA NETWORK
Pope Francis Prayer Intentions for OCTOBER 2017
Workers and the Unemployed. That all workers may receive respect and protection of their rights, and that the unemployed may receive the opportunity to contribute to the common good.
Children who struggle to match their gender identity with their biological sex should not be pushed into transgender therapies, but given ... continue reading
Why are cancer rates up to 14 times higher in countries with advanced healthcare? It's because there are more cancer survivors, and they ... continue reading
In 2016, voters sent Republicans to Washington with a mandate to end Obamacare. The law was spiteful, particularly towards Christians, ... continue reading
What does the Catholic Church say about vaccines? Woman faces jail for refusing to vaccinate child Watch
A woman faces jail time for contempt of court, should she refuse a judge's order to vaccinate her nine-year-old son. Rebecca Bredow is ... continue reading
The latest attempt to repeal Obamacare has failed. The Graham-Cassidy bill failed overnight leaving Obamacare as the law of the land. It is ... continue reading
by Catholic Online
- Will Europe return to its Christian roots?
- Day 1 - Novena to the Saints in Heaven for the saints on earth HD Video
- Day 2 - Novena to the Saints in Heaven for the saints on earth HD Video
- St. Hilarion: Saint of the Day for Saturday, October 21, 2017
- Evil George Soros transfers $18 billion to support abortion, destroy ...
- Pope continues work toward reconciliation with Methodists
- Daily Readings for Saturday, October 21, 2017
- Evil money - George Soros pays to start a revolution in America HD
- Daily Reading for Tuesday, October 24th, 2017 HD
- Daily Reading for Wednesday, October 25th, 2017 HD
- Daily Reading for Monday, October 23rd, 2017 HD
Learn about Catholic world
Inform - Inspire - Ignite
Catholic Online Saints
Your saints explained
Catholic Online Prayers
Prayers for every need
Catholic Online Bible
Complete bible online
Catholic Online News
Your news Catholic eye
Today's bible reading
Products and services we offer
Catholic Online Shopping
Catholic medals, gifts & books
The California Network
Inspiring streaming service
Learn the Catholic way